<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>revista-medicina-scolara</PublisherName>
<JournalTitle>The Journal of School and University Medicine</JournalTitle>
<PISSN/>
<EISSN/>
<Volume-Issue>Volume 6 Issue 2</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>April - June 2019</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>2019</Year>
<Month>05</Month>
<Day>24</Day>
</PubDate>
<ArticleType>Medical</ArticleType>
<ArticleTitle>OPTIMIZATION OF TYPE 1 DIABETES THERAPY THROUGH TECHNOLOGY</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>20</FirstPage>
<LastPage>22</LastPage>
<AuthorList>
<Author>
<FirstName>Morariu</FirstName>
<LastName>Diana</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>The use of modern technology in type 1 diabe tes (T1DM) management is one of the most discussed topics nowadays.
At present, the available devices include: CSII pumps, sensors augmented pumps (SAP), sensors
The use of modern technology in type 1 diabe tes (T1DM) management is one of the most discussed topics nowadays. In our country, the access to the use of various continuous subcutaneous insulin infusion (CSII) devices and blood glucose monitoring systems has increased. At present, the available devices in clude: CSII pumps, sensors augmented pumps (SAP), sensors augmented pumps with predictive low glu cose suspend monitoring systems (PLGM) which also offer alarms/prediction for hyperglycemia. There are several types of continuous glucose monitoring sys tems (CGMS):
A. intermittently viewed (iCGMS) which shows continuous glucose measurements retrospec tively at the time of checking [1];
B. real-time (rtCGMS) which uniformly tracks the glucose concentrations in the body’s interstitial fl uid, providing near real-time glucose data [1]. In this category, is also included the subcutaneous implanta
ble sensor which requires a minor surgical. Taking into consideration the wide variety of these systems, the essential aspect is to choose the most suitable system according to the safety profi le, accuracy and patient preference.
augmented pumps with predictive low glucose sus pend monitoring systems (PLGM) which also offer alarms/prediction for hyperglycemia.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>type 1 diabetes, technology</Keywords>
<URLs>
<Abstract>https://www.revista-medicina-scolara.ro/ubijournal-v1copy/journals/abstract.php?article_id=9260&title=OPTIMIZATION OF TYPE 1 DIABETES THERAPY THROUGH TECHNOLOGY</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>1. Danne T, Nimri R, Battelino T, et al. International con sensus on use of continuous glucose monitoring. Diabetes Care 2017;40:1631–1640.
2. Orchard TJ, Nathan DM, Zinman B, et al. Writing Group for the DCCT/EDIC Research Group. Association be tween 7 years of intensive treatment of type 1 diabetes and long term mortality. JAMA 2015;313:45–53 9.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359: 1577–1589.
4. American Diabetes Association 6. Glycemic Targets: Standards of Medical Care in 2018. Diabetes Care 2018;41(Suppl. 1):S55–S64 | https://doi.org/10.2337/dc18-S006.
5. National Institute for Health and Care Excellence (NICE). Diabetes (type 1 and type 2) in children and young people:
diagnosis and management, 2015. NICE guideline [NG18]. Lon don, U.K, www.nice.org.uk/guidance/ NG18.
6. David M. Maahs, Daniel De Salvo, Laura Pyle, Trang Ly, Laurel Messer, Paula Clinton, Emily Westfall, R. Paul Wadwa and Bruce Buckingham. Effect of Acetaminophen on CGM Glu cose in an Outpatient Setting. Diabetes Care 2015;38:e158–e159 | DOI: 10.2337/dc15-1096.
6. American Diabetes Association 7. Diabetes Technol ogy: Standards of Medical Care in Diabetes 2019 Diabetes Care 2019;42(Suppl. 1):S71–S80 | https://doi.org/10.2337/dc19-S007.
7. PlotnickLP, Clark L M, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and ado lescents with type1 diabetes. Diabetes Care 2003;26:1142–1146.
8. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies Jennifer L. Sherr, Martin Tauschmann, Ta dej Battelino, Martin de Bock, Gregory Forlenza, Rossana Ro man, Korey K. Hood, David M. Maahs. Pediatric Diabetes Oc tober 2018; 19 (Suppl. 27): 302–325. DOI: 10.1111/pedi.12731.
9. Danne T, Battelino T, Jarosz-Chobot P, et al. Estab lishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: ex perience of the PedPump Study in 17 countries. Diabetologia. 2008;51(9):1594-1601.
10. Hofer SE, Heidtmann B, Raile K, et al. Discontinua tion of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Ger many and Austria. Pediatr Diabetes. 2010;11(2):116-121.</References>
</References>
</Journal>
</Article>
</ArticleSet>